Assaying and PET Imaging of Ytrrium-90: 1&lt;&lt;34ppm&lt;0

Nickles, Robert J.; Roberts, Andrew; Nye, Jonathan A.; Converse, Alexander K.; Barnhart, Todd; Ávila‐Rodríguez, Miguel A.; Sundaresan, R.; Dick, David; Thomadsen, Bruce R.

doi:10.1109/nssmic.2004.1466619

Cited by 27 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, different authors have used the small positron emission to obtain high-resolution PET images of 90 Y-labeled radiopharmaceuticals [17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

90Y PET-based dosimetry after selective internal radiotherapy treatments

D’Arienzo

Chiaramida

Chiacchiararelli

et al. 2012

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…At present, different authors have used the small positron emission to obtain high-resolution PET images of 90 Y-labeled radiopharmaceuticals [17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

90Y PET-based dosimetry after selective internal radiotherapy treatments

D’Arienzo

Chiaramida

Chiacchiararelli

et al. 2012

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Consequently, 90 Y PET scan was proposed in order to assess the biodistribution [3] of 90 Y-labelled therapeutic agents. A 61-year-old woman was referred for treatment of chemorefractory colorectal liver metastasis.…”

mentioning

confidence: 99%

Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT

Lhommel

Goffette

Eynde

et al. 2009

Eur J Nucl Med Mol Imaging

147

104

View full text Add to dashboard Cite

The decay of 90 Y has a minor branch to the 0 + excited state [1], followed by an internal e + e − creation which happens in 32 out of one million decays [2]. Consequently, 90 Y PET scan was proposed in order to assess the biodistribution [3] of 90 Y-labelled therapeutic agents. A 61-year-old woman was referred for treatment of chemorefractory colorectal liver metastasis. Based on the pretreatment evaluation (including a diagnostic FDG PET/CT scan on day 1, and a prophylactic embolization of the right gastric and gastroduodenal arteries followed by a 99m Tc-MAA SPECT/CT scan on day 8), 1.3 GBq of 90 Y-labelled SIR-Spheres were administered by sequential catheterization of both liver lobes (day 15). Subsequently, a 30-min 90 Y TOF PET/CT scan was performed using a Philips GEMINI TF camera. In order to prevent saturation of the detectors, a copper ring of 2.5 mm thickness was inserted into the gantry to absorb the bremsstrahlung x-rays. The TOF data were reconstructed with attenuation and scatter correction using Philips RAMLA software (eight iterations, three subsets). An additional 20 min bremsstrahlung 90 Y-SPECT was acquired using a Trionix XLT20 triple head camera (medium energy collimator, 30% window centred on 90 keV). Data were reconstructed using OSEM (four iterations, six subsets). As illustrated, despite the differences in their respective uptake mechanism, 90 Y-PET better reflects the tumour heterogeneity assessed by FDG PET/CT (a necrotic core surrounded by active tumour margins) than traditional bremsstrahlung 90 Y-SPECT. This gain in resolution should therefore contribute to increasing the accuracy of the dose distribution into the tumours and their surrounding healthy tissues. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl

show abstract

“…Per megabecquerel, approximately 23,000 bremsstrahlung photons with energy higher than 50 keV are produced by interaction of the beta particle with tissue requiring acquisition in a wide energy window to maximize sensitivity and image formation [6]. Also per megabecquerel, 90Y emits 32 positrons per second with a maximum energy of 758 keV [7].…”

Section: Discussionmentioning

confidence: 99%

Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases

Kousik

Pankaj

Verma

et al. 2016

Indian J Gastroenterol

View full text Add to dashboard Cite

This study provides supportive evidence of the safety and efficacy on 90Y radioembolization for the treatment of unresectable HCC and hepatic metastases from various solid tumors. 90Y PET is a better radionuclide technique for assessing the hepatic and extrahepatic distribution of spheres following therapy compared to 90Y Bremsstrahlung SPECT. Thus, 90Y radioembolization is proving to be promising treatment with average disease control rates around 80 % and should be widely utilized.

show abstract

Assaying and PET Imaging of Ytrrium-90: 1<<34ppm<0

Cited by 27 publications

References 0 publications

90Y PET-based dosimetry after selective internal radiotherapy treatments

90Y PET-based dosimetry after selective internal radiotherapy treatments

Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT

Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases

Contact Info

Product

Resources

About